James Edgemond
2018
In 2018, James Edgemond earned a total compensation of $5.2M as Chief Financial Officer and Treasurer at United Therapeutics, a 39% decrease compared to previous year.
Compensation breakdown
| Change in Pension Value and Nonqualified Deferred Compensation Earnings | $467,161 |
|---|---|
| Non-Equity Incentive Plan | $731,250 |
| Option Awards | $3,382,085 |
| Salary | $645,833 |
| Other | $16,400 |
| Total | $5,242,729 |
Edgemond received $3.4M in option awards, accounting for 65% of the total pay in 2018.
Edgemond also received $467.2K of change in pension value and nonqualified deferred compensation earnings, $731.3K in non-equity incentive plan, $645.8K in salary and $16.4K in other compensation.
Rankings
In 2018, James Edgemond's compensation ranked 1,893rd out of 14,244 executives tracked by ExecPay. In other words, Edgemond earned more than 86.7% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 1,893 out of 14,244 | 87th |
Division Manufacturing | 679 out of 5,759 | 88th |
Major group Chemicals And Allied Products | 224 out of 2,122 | 89th |
Industry group Drugs | 177 out of 1,811 | 90th |
Industry Pharmaceutical Preparations | 135 out of 1,385 | 90th |
Source: SEC filing on April 29, 2019.
Edgemond's colleagues
We found three more compensation records of executives who worked with James Edgemond at United Therapeutics in 2018.